BCTX Stock Chart & Stats
$7.28
-$0.02(-3.38%)
At close: 4:00 PM EST
$7.28
-$0.02(-3.38%)
Day’s Range― - ―
52-Week Range$2.60 - $31.10
Previous Close$0.41
Volume996.24K
Average Volume (3M)71.25K
Market Cap
$28.40M
Enterprise Value-$1.60M
Total Cash (Recent Filing)$22.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.20
Shares Outstanding8,699,787
10 Day Avg. Volume65,395
30 Day Avg. Volume71,255
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit60.36
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Net-cash / Low LeverageA net-cash position with no reported debt materially reduces solvency and refinancing risk for a pre-revenue biotech. This durable strength gives management flexibility to prioritize clinical development and partnerships without near-term debt servicing constraints.
Improving Equity And Asset BaseRising shareholders' equity and assets signal successful capital raises or retained financing that bolster runway. A stronger capital base improves the firm's ability to fund multi-phase clinical programs and reduces the immediacy of fundraising needs over the medium term.
Focused Immunotherapy PipelineA clear strategic focus on cell-based immunotherapies and an identifiable lead clinical asset (Bria-IMT) aligns the company with enduring growth in immuno-oncology. This concentrated pipeline supports coherent R&D prioritization and makes partnerships or licensing more actionable long term.
Bears Say
Pre-revenue And Persistent LossesZero product revenue combined with substantial recurring operating losses is a structural constraint: without commercialization or recurring partner revenue, the company must continually access capital markets to fund operations, increasing dilution risk and governance pressure over time.
Elevated Cash Burn And Worsening FCFSustained and rising cash burn materially shortens runway and heightens reliance on external financing. For a development-stage biotech this raises the probability of dilutive capital raises or slowed development timelines if funding conditions tighten, creating persistent execution risk.
Historical Equity Volatility / Funding RiskPast episodes of negative equity and volatility indicate recurring funding stress and a track record of dilutive financing. This history signals an ongoing structural vulnerability: future capital needs could again force equity issuance or unfavorable deals that impair long-term shareholder returns.
BriaCell Therapeutics News
BCTX FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was $2.60 and its highest was $31.10 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is $28.40M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Oct 22, 2026 which is in 112 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Jun 09, 2026. The company reported -$0.952 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.952.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 8,699,787 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -$0.952 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.189%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in BCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.49%
12-Months-Change
Fundamentals
Return on Equity
-221.75%
Trailing 12-Months
Asset Growth
235.47%
Trailing 12-Months
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Ownership Overview
37.66% Insiders
4.26% Other Institutional Investors
58.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---